TargetBeta
KMT2A
lysine methyltransferase 2A · also TRX1, HRX, ALL-1, HTRX1 · PHD finger proteins
4 programs in company-led studies act on KMT2A, from 4 companies: 3 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (3 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| ziftomenibrule | Kura Oncology | phase 3 | 66 running | – | NCIt |
| revumenibrule | Syndax Pharmaceuticals | phase 3 | 64 running | MEN1 | NCIt |
| bleximenib | Johnson & Johnson | phase 3 | 42 running | MEN1 | a judged reading |
| icovamenibrule | Biomea Fusion | phase 2 | 72 running | – | NCIt |
Also acted on by the same programs
Conditions their studies are in
- Leukemia, Myeloid, Acute, 4 programs
- Hematologic Neoplasms, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Colorectal Neoplasms, 1 program
- Diabetes Mellitus, Type 1, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Gastrointestinal Stromal Tumors, 1 program
- Leukemia, 1 program
- Myelodysplastic Syndromes, 1 program
- Precursor Cell Lymphoblastic Leukemia-Lymphoma, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Dec 2026ziftomenib · Kura Oncology · phase 3 · NCT06001788
- Feb 2027revumenib · Syndax Pharmaceuticals · phase 3 · NCT06226571
- Mar 2027icovamenib · Biomea Fusion · phase 2 · NCT07502495
- Dec 29, 2028bleximenib · Johnson & Johnson · phase 3 · NCT04811560
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.